BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 24240137)

  • 1. FDG-PET/CT-based restaging may alter initial management decisions and clinical outcomes in patients with locally advanced pancreatic carcinoma planned to undergo chemoradiotherapy.
    Topkan E; Parlak C; Yapar AF
    Cancer Imaging; 2013 Oct; 13(3):423-8. PubMed ID: 24240137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical usefulness of ¹⁸F-fluorodeoxyglucose-positron emission tomography in patients with locally advanced pancreatic cancer planned to undergo concurrent chemoradiation therapy.
    Chang JS; Choi SH; Lee Y; Kim KH; Park JY; Song SY; Cho A; Yun M; Lee JD; Seong J
    Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):126-33. PubMed ID: 25015206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of gross tumor volume delineated by FDG-PET-CT based radiotherapy treatment planning in patients with locally advanced pancreatic cancer treated with chemoradiotherapy.
    Parlak C; Topkan E; Onal C; Reyhan M; Selek U
    Radiat Oncol; 2012 Mar; 7():37. PubMed ID: 22429939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of metabolic 18FDG-PET response on outcomes in patients with locally advanced pancreatic carcinoma treated with definitive concurrent chemoradiotherapy.
    Topkan E; Parlak C; Kotek A; Yapar AF; Pehlivan B
    BMC Gastroenterol; 2011 Nov; 11():123. PubMed ID: 22074002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of
    Wilson JM; Mukherjee S; Brunner TB; Partridge M; Hawkins MA
    Clin Oncol (R Coll Radiol); 2017 Jun; 29(6):370-377. PubMed ID: 28190636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of dual-time combined 18-fluorodeoxyglucose positron emission tomography and computed tomography in the staging and restaging workup of locally advanced rectal cancer, treated with preoperative chemoradiation therapy and radical surgery.
    Capirci C; Rubello D; Pasini F; Galeotti F; Bianchini E; Del Favero G; Panzavolta R; Crepaldi G; Rampin L; Facci E; Gava M; Banti E; Marano G
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1461-9. PubMed ID: 19419820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges in using ¹⁸F-fluorodeoxyglucose-PET-CT to define a biological radiotherapy boost volume in locally advanced pancreatic cancer.
    Wilson JM; Mukherjee S; Chu KY; Brunner TB; Partridge M; Hawkins M
    Radiat Oncol; 2014 Jun; 9():146. PubMed ID: 24962658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Added value of digital FDG-PET/CT in disease staging and restaging in patients with resectable or borderline resectable pancreatic cancer.
    de Jong TL; Koopman D; van der Worp CAJ; Stevens H; Vuijk FA; Vahrmeijer AL; Mieog JSD; de Groot JB; Meijssen MAC; Nieuwenhuijs VB; Lioe-Fee GO; Jager PL; Patijn GA
    Surg Oncol; 2023 Apr; 47():101909. PubMed ID: 36739788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative Value of Restaging MRI, CT, and FDG-PET Scan After Preoperative Chemoradiation for Rectal Cancer.
    Schneider DA; Akhurst TJ; Ngan SY; Warrier SK; Michael M; Lynch AC; Te Marvelde L; Heriot AG
    Dis Colon Rectum; 2016 Mar; 59(3):179-86. PubMed ID: 26855391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDG-PET might not contribute to improving survival in patients with locally advanced inoperable esophageal cancer.
    Jingu K; Umezawa R; Yamamoto T; Takeda K; Ishikawa Y; Takahashi N; Kadoya N; Matsushita H
    Int J Clin Oncol; 2019 Aug; 24(8):927-933. PubMed ID: 30863993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Pretreatment Combined (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging on Radiation Therapy Treatment Decisions in Locally Advanced Breast Cancer.
    Ng SP; David S; Alamgeer M; Ganju V
    Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):111-7. PubMed ID: 26279029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer.
    Groheux D; Hindié E; Marty M; Espié M; Rubello D; Vercellino L; Bousquet G; Ohnona J; Toubert ME; Merlet P; Misset JL
    Eur J Radiol; 2014 Oct; 83(10):1925-33. PubMed ID: 24985086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial.
    Nestle U; Schimek-Jasch T; Kremp S; Schaefer-Schuler A; Mix M; Küsters A; Tosch M; Hehr T; Eschmann SM; Bultel YP; Hass P; Fleckenstein J; Thieme A; Stockinger M; Dieckmann K; Miederer M; Holl G; Rischke HC; Gkika E; Adebahr S; König J; Grosu AL;
    Lancet Oncol; 2020 Apr; 21(4):581-592. PubMed ID: 32171429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
    Piessen G; Petyt G; Duhamel A; Mirabel X; Huglo D; Mariette C
    Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma.
    Kibel AS; Dehdashti F; Katz MD; Klim AP; Grubb RL; Humphrey PA; Siegel C; Cao D; Gao F; Siegel BA
    J Clin Oncol; 2009 Sep; 27(26):4314-20. PubMed ID: 19652070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of PET/CT in the clinical management of locally advanced pancreatic cancer.
    Picchio M; Giovannini E; Passoni P; Busnardo E; Landoni C; Giovacchini G; Bettinardi V; Crivellaro C; Gianolli L; Di Muzio N; Messa C
    Tumori; 2012; 98(5):643-51. PubMed ID: 23235761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy.
    Capirci C; Rampin L; Erba PA; Galeotti F; Crepaldi G; Banti E; Gava M; Fanti S; Mariani G; Muzzio PC; Rubello D
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1583-93. PubMed ID: 17503039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.